Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early onset dementia.
Fadil H, Borazanci A, Ait Ben Haddou E, Yahyaoui M, Korniychuk E, Jaffe SL, Minagar A. Fadil H, et al. Among authors: borazanci a. Int Rev Neurobiol. 2009;84:245-62. doi: 10.1016/S0074-7742(09)00413-9. Int Rev Neurobiol. 2009. PMID: 19501722 Review.
Movement disorders.
Harris MK, Shneyder N, Borazanci A, Korniychuk E, Kelley RE, Minagar A. Harris MK, et al. Among authors: borazanci a. Med Clin North Am. 2009 Mar;93(2):371-88, viii. doi: 10.1016/j.mcna.2008.09.002. Med Clin North Am. 2009. PMID: 19272514 Review.
Stroke rehabilitation.
Kelley RE, Borazanci AP. Kelley RE, et al. Among authors: borazanci ap. Neurol Res. 2009 Oct;31(8):832-40. doi: 10.1179/016164109X12445505689689. Neurol Res. 2009. PMID: 19723452 Review.
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Yan Y, Li Y, Fu Y, Yang L, Su L, Shi K, Li M, Liu Q, Borazanci A, Liu Y, He Y, Bennett JL, Vollmer TL, Shi FD. Yan Y, et al. Among authors: borazanci a. Sci China Life Sci. 2016 Dec;59(12):1270-1281. doi: 10.1007/s11427-015-4997-y. Epub 2016 Feb 26. Sci China Life Sci. 2016. PMID: 26920678 Free PMC article.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
11 results